.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
UBS
Julphar
Queensland Health
Medtronic
Baxter
Covington
McKesson
Johnson and Johnson
Teva

Generated: November 23, 2017

DrugPatentWatch Database Preview

Claims for Patent: 8,937,062

« Back to Dashboard

Claims for Patent: 8,937,062

Title:Compositions and methods for treating, reducing, ameliorating, or preventing infections caused by antibacterial drug-resistant bacteria
Abstract: Compositions comprise a fluoroquinolone having Formulae I-VIII for treating, reducing, ameliorating, or preventing infections caused by some bacteria that are resistant to an antibacterial drug. Methods for treating, reducing, ameliorating, or preventing such infections use such compositions.
Inventor(s): Tyle; Praveen (Pittsford, NY), Gupta; Pramod Kumar (Pittsford, NY), Norton; Susan E. (Rochester, NY), Brunner; Lynne (Webster, NY), Blondeau; Joseph (Saskatoon, CA)
Assignee: Bausch & Lomb Incorporated (Rochester, NY)
Application Number:12/051,289
Patent Claims: 1. A method for treating, reducing, or ameliorating all infection in a subject, the method comprising administering to said subject in need thereof a composition comprising: (a) a fluoroquinolone having Formula IV or a salt thereof present in an amount effective to treat, reduce, or ameliorate an infection caused by ofloxacin-resistant Enterobacteriaceae with MIC.sub.90 range of 4-32 .mu.g/ml in vitro, ofloxacin-resistant S. aureus with MIC.sub.90 range of 0.5-8 .mu.g/ml in vitro, levofloxacin-resistant S. pneumonia with MIC.sub.90 range of 0.5-8 .mu.g/ml in vitro, gentamicin-resistant S. aureus with MIC.sub.90 range of 0.006-8 .mu.g/ml in vitro, ampicillin-resistant H. influenza with MIC.sub.90 less than or equal to 0.06 .mu.g/ml in vitro, or vancomycin-resistant S. aureus with MIC.sub.90 range of 1-4 .mu.g/ml in vitro; or (b) a fluoroquinolone having Formula VI present in an amount effective to treat, reduce, or ameliorate an infection caused by gentamicin-resistant S. aureus with MIC.sub.90 range of 0.006-4 .mu.g/m in vitro or ampicillin-resistant H. influenza with MIC.sub.90 less than or equal to 0.06 .mu.g/ml in vitro; ##STR00007##

2. The method of claim 1, wherein the composition is administered topically, orally, or systemically.

3. The method of claim 1, where the composition is administered topically.

4. The method of claim 1, wherein the infection is an infection of an eye, ear, respiratory system, or a combination thereof.

5. A method for treating, reducing, or ameliorating an infection in a subject, the method comprising: (a) ascertaining that a specimen from a site of infection contains a bacterium that is resistant to an antibacterial drug that is selected from the group consisting of gentamycin, vancomycin, ofloxacin, ciprofloxacin, and levofloxacin; and (b) administering to said subject in need thereof a composition comprising (i) a fluoroquinolone having Formula IV or a salt thereof present in an amount effective to treat, reduce, or ameliorate an infection caused by ofloxacin-resistant Enterobacteriaceae with MIC.sub.90 range of 4-32 .mu.g/ml in vitro, ofloxacin-resistant S. aureus with MIC.sub.90 range of 0.5-8 .mu.g/ml in vitro, levofloxacin-resistant S. pneumonia with MIC.sub.90 range of 0.5-8 .mu.g/ml in vitro, gentamicin-resistant S. aureus with MIC.sub.90 range of 0.006-8 .mu.g/ml in vitro, ampicillin-resistant H. influenza with MIC.sub.90 less than or equal to 0.06 .mu.g/ml in vitro, or vancomycin-resistant S. aureus with MIC.sub.90 range of 1-4 .mu.g/ml in vitro; or (ii) a fluoroquinolone having Formula VI present in an amount effective to treat, reduce, or ameliorate an infection caused by, ofloxacin-resistant S. aureus with MIC.sub.90 range of 0.5-8 .mu.g/ml in vitro or ampicillin-resistant H. influenza with MIC.sub.90 less than or equal to 0.06 .mu.g/ml in vitro; ##STR00008##
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Cantor Fitzgerald
Chinese Patent Office
Medtronic
Federal Trade Commission
Deloitte
US Army
US Department of Justice
Julphar
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot